Tevogen Bio appoints cell therapy expert as global clinical development lead 

Tevogen Bio on Wednesday said it appointed Delores Grosso as global clinical development lead, to implement the company’s expanding clinical trial portfolio.

The Warren-based late-stage clinical biotechnology company specializes in the development of cellular immunotherapies in virology, neurology and oncology.

Grosso has spent more than 40 years in health care, the first 15 years as a critical care nurse at Thomas Jefferson University in Philadelphia. She earned a Master of Science degree in 1986 and a post-master’s Nurse Practitioner degree in 1995, both in critical care nursing, from the University of Pennsylvania. In 1996, she joined the Blood and Marrow Transplant Program at Thomas Jefferson University as a nurse practitioner.

Over the next 25 years, Drosso expanded her career in cellular therapy research under the mentorship of acclaimed oncologist Dr. Neal Flomenberg. In 2009, she earned a Doctor of Nursing Practice investigating donor selection strategies in haploidentical hematopoietic stem cell transplantation at Thomas Jefferson University. Later that year, she was appointed to the faculty of Jefferson Medical College, ultimately achieving the rank of associate professor in research in early 2022.

Grosso has written over 20 investigator-initiated research protocols with multiple first and last author publications. She has served as a research mentor to numerous physician fellows, including several participating in a Master’s in Pharmacology Program at Jefferson. In 2021, she won the Excellence in Clinical Research Award from the Sidney Kimmel Cancer Center at Thomas Jefferson University in recognition of her prolific research activities and contributions to the Cancer Center’s clinical research efforts.

“After 40 years caring for patients, I highly value Tevogen Bio’s commitment to developing next-generation affordable immunotherapies,” Grosso stated. “As a researcher, I am excited to participate in the expansion of Tevogen’s precision T-cell platform for the novel treatment of disease.”

“Since our foundation in 2020, our advanced science and business models have led us to become one of the most successful startup biotech companies. As Tevogen’s founder, I am pleased to welcome Dr. Grosso’s unique experience and unwavering passion to our leadership team,” Tevogen CEO Dr. Ryan Saadi said.